Top 5 Large-Cap Stocks In Biotechnology Industry With Highest Gross Margins (CELG, BIIB, AMGN, GILD, GENZ)

Below are the top five large-cap biotechnology stocks on the NYSE and NASDAQ in terms of gross margins.

The trailing-twelve-month gross margins at Celgene Corporation (NASDAQ: CELG)are 91.97%. Analysts at Piper Jaffray initiated coverage of CELG with an “overweight” rating. Read more about this company here.

The trailing-twelve-month gross margins at Biogen Idec Inc (NASDAQ: BIIB)are 91.27%. BIIB’s shares gained 16.16% over the past 52 weeks, while the S&P 500 index has jumped by 41.67% in the same period. Read more about this company here.

The trailing-twelve-month gross margins at Amgen Inc (NASDAQ: AMGN)are 85.73%. AMGN had $13.44 billion of total cash in the most recent quarter. Read more about this company here.

The trailing-twelve-month gross margins at Gilead Sciences Inc (NASDAQ: GILD)are 77.24%. GILD’s trailing-twelve-month ROE stands at 49.55%. Read more about this company here.

The trailing-twelve-month gross margins at Genzyme Corporation (NASDAQ: GENZ)are 70.47%. GENZ’s shares gained just 1.95% over the past 52 weeks, while the S&P 500 index has jumped by 41.67% in the same period. Read more about this company here.